Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Amphastar Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:50 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001297184-26-000047
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Selling, distribution, and marketing | 13,335 | 10,235 | 25,262 | 22,101 |
| General and administrative | 18,242 | 13,991 | 36,270 | 29,987 |
| Research and development | 22,164 | 20,080 | 48,901 | 40,176 |
| Total operating expenses | 53,741 | 44,306 | 110,433 | 92,264 |
| Income from operations | 39,729 | 42,184 | 53,359 | 79,477 |
| Non-operating expenses: | ||||
| Interest income | 2,287 | 1,921 | 4,687 | 4,010 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Amphastar Pharmaceuticals's R&D?
- Amphastar Pharmaceuticals (AMPH) reported R&D of $22.16M in Q2 2026.
- How has Amphastar Pharmaceuticals's R&D changed year-over-year?
- Amphastar Pharmaceuticals's R&D increased by 10.4% year-over-year, from $20.08M to $22.16M.
- What is the long-term trend for Amphastar Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's R&D has grown at a 8.9% compound annual growth rate (CAGR), from $60.93M to $85.84M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Amphastar Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude